After the six Industrial Dialogues that took place throughout the first semester of 2017, some of the co-designed responsible tools have been tested during the SMART-map pilot phase. In fact, the aim of the pilots (one for each innovation topic) was to evaluate if the responsible tools could be effectively implemented within the innovation pipelines of innovation companies.
The precision medicine pilot activity was carried out in Spain, at IMEGEN, a biomedical biotechnological company based in Valencia, that is also a partner of the project. The IMEGEN product on which the pilot has focused is called IMExoma, a specific DNA sequencing technique. The chosen tool was the End User Experience Advisory Panel, involving patients and doctors.
The 3D printing in biomedicine pilot took place with the involvement of the companies of the SYMBIONICA consortium, a Research and Innovation Action granted by the European Commission under Horizon 2020. The project is coordinated by the SINTEA Plustek srl, an Italian SME, and the two chosen tools tested in the pilot were RRI Training for the SYMBIONICA consortium and a Multi-stakeholder Workshop with external stakeholders to start a multi-actor discussion on new rules for 3D printing process in biomedicine.
The industrial actors which participated in the synthetic biology pilot in UK were Cambridge Consultants, Defence, Science and Technology Laboratory (an executive agency of the Ministry of Defence), and Innovation and Sparkling Science Ltd, a micro biotech company. Each of them was asked to learn from their own experiences and to understand what it means to institutionalise Responsible Research and Innovation. The objective was to produce a small number of examples as input to a repository of short learning cases, which was the selected tool to be tested.